Document:

Exhibit 4.3

 

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS.  NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.

 

N30 PHARMACEUTICALS, INC.

 

SECOND AMENDED AND RESTATED WARRANT TO PURCHASE

COMMON STOCK

 

THIS CERTIFIES THAT, for value received, HORIZON CREDIT II LLC, as successor in interest to COMPASS HORIZON FUNDING COMPANY LLC (“Holder”) and its assignees are entitled to subscribe for and purchase Twenty Six Thousand Seven Hundred Seventy Five (26,775) fully paid and nonassessable shares of Common Stock (as may be adjusted from time to time pursuant to Section 4 hereof, the “Shares”) of N30 PHARMACEUTICALS, INC., a Delaware corporation (f/k/a N30 PHARMACEUTICALS, LLC) (the “Company”), at the price of Eight and 40/100 Dollars ($8.40) per share (such price and such other price as shall result, from time to time, from the adjustments specified in Section 4 hereof is herein referred to as the “Warrant Price”), subject to the provisions and upon the terms and conditions hereinafter set forth.  As used herein,  the term “Date of Grant” shall mean February 18, 2011.  This Warrant hereby amends and restates in its entirety that certain Amended and Restated Warrant issued by N30 Pharmaceuticals, Inc. to HORIZON CREDIT II LLC with a date of grant of February 11, 2011 (the “Second Warrant”) to reflect a recapitalization of the Company’s capital stock in which all outstanding shares of Preferred Stock (including the Series D Preferred Stock), were automatically converted into shares of Common Stock as of September 23, 2014, after which the Company implemented a four-for-one reverse stock split of all of its outstanding capital stock. Upon execution and delivery of this Second Amended and Restated Warrant to HORIZON CREDIT II LLC, the Second Warrant shall be terminated, and shall no longer be valid or have any force or effect.

 

1.                                      Term.  The purchase right represented by this Warrant is exercisable, in whole or in part, at any time and from time to time from the Date of Grant through ten (10) years after the Date of Grant.

 

2.                                      Method of Exercise; Payment; Issuance of New Warrant.

 

(a)                                 Subject to Section 1 hereof, the purchase right represented by this Warrant may be exercised by the holder hereof, in whole or in part and from time to time, at the election of the holder hereof, by (a) the surrender of this Warrant (with the notice of exercise substantially in the form attached hereto as Exhibit A-1 duly completed and executed) at the principal office of the

 

 

Company and by the payment to the Company, by certified or bank check, or by wire transfer to an account designated by the Company (a “Wire Transfer”) of an amount equal to the then applicable Warrant Price multiplied by the number of Shares then being purchased; (b) if in connection with a registered public offering of the Company’s securities, the surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A-2 duly completed and executed) at the principal office of the Company together with notice of arrangements reasonably satisfactory to the Company for payment to the Company either by certified or bank check or by Wire Transfer from the proceeds of the sale of securities to be sold by the holder in such public offering of an amount equal to the then applicable Warrant Price per Share multiplied by the number of Shares then being purchased; or (c) exercise of the “net issuance” right provided for in Section 10.2 hereof.

 

(b)                                 The person or persons in whose name(s) any certificate(s) representing Shares shall be issuable upon exercise of this Warrant shall be deemed to have become the holder(s) of record of, and shall be treated for all purposes as the record holder(s) of, the shares represented thereby (and such shares shall be deemed to have been issued) immediately prior to the close of business on the date or dates upon which this Warrant is exercised.

 

(c)                                  In the event of any exercise of the rights represented by this Warrant, certificates for the securities so purchased (in the case of certificated securities) and a copy of the Company’s Certificate of Incorporation, as amended, restated, supplemented or otherwise modified from time to time (the “Certificate of Incorporation”) shall be delivered to the holder hereof as soon as possible and in any event within thirty (30) days after such exercise and, unless this Warrant has been fully exercised or expired, a new Warrant representing the portion of the Shares, if any, with respect to which this Warrant shall not then have been exercised shall also be issued to the holder hereof as soon as possible and in any event within such thirty-day period; provided, however, at such time as the Company is subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, if requested by the holder of this Warrant, the Company shall cause its transfer agent to deliver the certificate representing Shares issued upon exercise of this Warrant to a broker or other person (as directed by the holder exercising this Warrant) within the time period required to settle any trade made by the holder after exercise of this Warrant.

 

3.                                      Shares Fully Paid; Reservation of Shares.  All Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance pursuant to the terms and conditions herein, be fully paid and nonassessable, and free from all preemptive rights and taxes, liens and charges with respect to the issue thereof, except for any such rights, taxes, liens and charges arising under the provisions of the Certificate of Incorporation.  During the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized, and reserved for the purpose of the issue upon exercise of the purchase rights evidenced by this Warrant, a sufficient number of shares of its Common Stock to provide for the exercise of the rights represented by this Warrant.

 

2

 

4.                                      Adjustment of Warrant Price and Number of Shares.  The number and kind of securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows:

 

(a)                                 Reclassification or Merger.  In case of any reclassification or change of securities of the class issuable upon exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision or combination), or in case of any merger of the Company with or into another corporation or limited liability company (other than a merger with another corporation or limited liability company in which the Company is the acquiring and the surviving corporation or limited liability company and which does not result in any reclassification or change of outstanding securities issuable upon exercise of this Warrant), or in case of any sale of all or substantially all of the assets of the Company, the Company, or such successor or purchasing corporation or limited liability company, as the case may be, shall duly execute and deliver to the holder of this Warrant a new Warrant (in form and substance satisfactory to the holder of this Warrant), so that the holder of this Warrant shall have the right to receive upon exercise of this Warrant, at a total purchase price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, and in lieu of the shares of Common Stock theretofore issuable upon exercise of this Warrant, (i) the kind and amount of shares of stock, other securities, money and property receivable upon such reclassification, change, merger or sale by a holder of the number of shares of Common Stock then purchasable under this Warrant, or (ii) in the case of such a merger or sale in which the consideration paid consists all or in part of assets other than securities of the successor or purchasing corporation or limited liability company, at the option of the holder of this Warrant, the securities of the successor or purchasing corporation or limited liability company having a value at the time of the transaction equivalent to the value of the Common Stock purchasable upon exercise of this Warrant at the time of the transaction.  Any new Warrant shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 4.  The provisions of this Section 4(a) shall similarly apply to successive reclassifications, changes, mergers and sales.

 

(b)                                 Subdivision or Combination of Shares.  If the Company at any time while this Warrant remains outstanding and unexpired shall subdivide or combine its outstanding shares of Common Stock, the Warrant Price shall be proportionately decreased and the number of Shares issuable hereunder shall be proportionately increased in the case of a subdivision and the Warrant Price shall be proportionately increased and the number of Shares issuable hereunder shall be proportionately decreased in the case of a combination.

 

(c)                                  Dividends and Other Distributions.  If the Company at any time while this Warrant is outstanding and unexpired shall (i) pay a dividend with respect to Common Stock payable in Common Stock, then the Warrant Price shall be adjusted, from and after the date of determination of members entitled to receive such dividend or distribution, to that price determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of

 

3

 

shares of Common Stock outstanding immediately after such dividend or distribution; or (ii) make any other distribution with respect to Common Stock (except any distribution specifically provided for in Sections 4(a) and 4(b)), then, in each such case, provision shall be made by the Company such that the holder of this Warrant shall receive upon exercise of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of shares of Common Stock as of the record date fixed for the determination of the members of the Company entitled to receive such dividend or distribution.

 

(d)                                 Adjustment of Number of Shares.  Upon each adjustment in the Warrant Price, the number of shares of Common Stock purchasable hereunder shall be adjusted, rounding down to the nearest whole share, to the product obtained by multiplying the number of Shares purchasable immediately prior to such adjustment in the Warrant Price by a fraction, the numerator of which shall be the Warrant Price immediately prior to such adjustment and the denominator of which shall be the Warrant Price immediately thereafter.

 

(e)                                  Antidilution Rights.  There are no antidilution rights applicable to the shares of Common Stock purchasable hereunder, set forth in the Certificate of Incorporation.  The Company shall provide the holder hereof with any restatement, amendment, modification or waiver of the Certificate of Incorporation within a reasonable period of time following the same being made.

 

5.                                      Notice of Adjustments.  Whenever the Warrant Price or the number of Shares purchasable hereunder shall be adjusted pursuant to Section 4 hereof, the Company shall make a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant Price and the number of Shares purchasable hereunder after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (without regard to Section 12 hereof, by first class mail, postage prepaid) to the holder of this Warrant.  In addition, whenever the conversion price or conversion ratio of the Common Stock shall be adjusted, the Company shall make a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the conversion price or ratio of the Common Stock after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (without regard to Section 12 hereof, by first class mail, postage prepaid) to the holder of this Warrant.

 

6.                                      Fractional Shares.  No fractional shares of Common Stock will be issued in connection with any exercise hereunder, but in lieu of such fractional shares the Company shall make a cash payment therefor based on the fair market value of the Common Stock on the date of exercise as reasonably determined in good faith by the Company’s Board of Directors.

 

7.                                      Compliance with Act; Disposition of Warrant or Shares of Common Stock.

 

(a)                                 Compliance with Act.  The holder of this Warrant, by acceptance hereof, agrees that this Warrant, and the shares of Common Stock to be issued upon exercise hereof, are being acquired for investment and that such holder will not offer, sell or otherwise dispose of this

 

4

 

Warrant, or any shares of Common Stock to be issued upon exercise hereof except under circumstances which will not result in a violation of the Act or any applicable state securities laws.  Upon exercise of this Warrant, unless the Shares being acquired are registered under the Act and any applicable state securities laws or an exemption from such registration is available, the holder hereof shall confirm in writing that the shares of Common Stock so purchased are being acquired for investment and not with a view toward distribution or resale in violation of the Act and shall confirm such other matters related thereto as may be reasonably requested by the Company.  This Warrant and all shares of Common Stock issued upon exercise of this Warrant (unless registered under the Act and any applicable state securities laws) shall be stamped or imprinted with a legend in substantially the following form:

 

“THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS.  NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THE WARRANT UNDER WHICH THESE SECURITIES WERE ISSUED, DIRECTLY OR INDIRECTLY.”

 

Said legend shall be removed by the Company, upon the request of a holder, at such time as the restrictions on the transfer of the applicable security shall have terminated.  In addition, in connection with the issuance of this Warrant, the holder specifically represents to the Company by acceptance of this Warrant as follows:

 

(1)                                 The holder is aware of the Company’s business affairs and financial condition, and has acquired information about the Company sufficient to reach an informed and knowledgeable decision to acquire this Warrant.  The holder is acquiring this Warrant for its own account for investment purposes only and not with a view to, or for the resale in connection with, any “distribution” thereof in violation of the Act.

 

(2)                                 The holder understands that this Warrant has not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the holder’s investment intent as expressed herein.

 

(3)                                 The holder further understands that this Warrant must be held indefinitely unless subsequently registered under the Act and qualified under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available.  The holder is aware of the provisions of Rule 144, promulgated under the Act.

 

(4)                                 The holder is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated under the Act.

 

5

 

(b)                                 Disposition of Warrant or Shares.  With respect to any offer, sale or other disposition of this Warrant or the shares of Common Stock acquired pursuant to the exercise of this Warrant prior to registration of such Warrant or shares, the holder hereof agrees to comply with all applicable provisions of the Certificate of Incorporation as well as the applicable provisions (including without limitation the provision governing disposition of shares of capital stock) set forth in that certain Amended and Restated Investor Rights Agreement by and among the Company and the other parties thereto dated as of September 24, 2014 (the “Rights Agreement), that certain Amended and Restated Right of First Refusal and Co-Sale Agreement by and among the Company and the other parties thereto dated as of September 24, 2014 (the “ROFR Agreement), that certain Amended and Restated Voting Agreement by and among the Company and the other parties thereto dated as of September 24, 2014 (the “Voting Agreement” and together with the Rights Agreement and the ROFR Agreement, the “Investor Agreements”).  Upon exercise of this Warrant, at the Company’s request the holder of this Warrant shall execute and become a party to each of the Investor Agreements to carry out the intent of this Section 7(b).

 

(c)                                  Applicability of Restrictions.  Neither any restrictions of any legend described in this Warrant nor the requirements of Section 7(b) above shall apply to any transfer of, or grant of a security interest in, this Warrant (or the Common Stock obtainable upon exercise hereof) or any part hereof to any affiliate of the holder if the holder is a corporation.  In addition, the holder of this Warrant may transfer the Warrant (but not any Common Stock obtainable upon exercise hereof) to (x) a lender to the holder or (y) any corporation, company, limited liability company, limited partnership, partnership, or other person managed or sponsored by Horizon Technology Finance Corporation (“HRZN”) or in which HRZN has an interest; provided, however, in any such transfer, the transferee shall upon the Company’s request agree in writing to be bound by the terms and conditions of this Warrant and as if an original holder hereof.

 

8.                                      Rights as Shareholders; Information.  No holder of this Warrant, as such, shall be entitled to vote or receive dividends or be deemed the holder of Common Stock or any other securities of the Company which may at any time be issuable upon the exercise hereof for any purpose, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, any of the rights of a shareholder of the Company or any right to vote for the election of directors or upon any matter submitted to members at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become deliverable, as provided herein.  Notwithstanding the foregoing, the Company will transmit to the holder of this Warrant such information, documents and reports as are generally distributed to the holders of any class or series of the securities of the Company concurrently with the distribution thereof to the shareholders.

 

9.                                      Registration Rights.  The shares of Common Stock for which this Warrant is exercisable shall be “Registrable Securities,” as such term is defined in the Rights Agreement, with the following exceptions and clarifications:

 

6

 

(1)                                 The holder will not have the right to demand registration, but can otherwise participate in any registration demanded by others.

 

10.                               Additional Rights

 

10.1                        Acquisition Transactions.  The Company shall provide the holder of this Warrant with at least ten (10) days’ written notice prior to closing thereof of the terms and conditions of any of the following transactions: (i) the sale, lease, exchange, conveyance or other disposition of all or substantially all of the Company’s property or business, or (ii) its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or other reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of (in each case, a “Sale Transaction”).

 

10.2                        Right to Convert Warrant into Shares:  Net Issuance.

 

(a)                                 Right to Convert.  In addition to and without limiting the rights of the holder under the terms of this Warrant, the holder shall have the right to convert this Warrant or any portion thereof (the “Conversion Right”) into shares of Common Stock as provided in this Section 10.2 at any time or from time to time during the term of this Warrant.  Upon exercise of the Conversion Right with respect to a particular number of shares subject to this Warrant (the “Converted Warrant Shares”), the Company shall deliver to the holder (without payment by the holder of any exercise price or any cash or other consideration) that number of duly authorized, fully paid and nonassessable shares of Common Stock as is determined according to the following formula:

 

X =   B - A

     Y

 

Where:  X =                                                        the number of shares of Common Stock that shall be issued to holder

 

Y =                                                     the fair market value of one share of Common Stock

 

A =                                                     the aggregate Warrant Price of the specified number of Converted Warrant Shares immediately prior to the exercise of the Conversion Right (i.e., the number of Converted Warrant Shares multiplied by the Warrant Price)

 

B =                                                     the aggregate fair market value of the specified number of Converted Warrant Shares (i.e., the number of Converted Warrant Shares multiplied by the fair market value of one Converted Warrant Shares)

 

No fractional shares shall be issuable upon exercise of the Conversion Right, and, if the number of shares to be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay to the holder an amount in cash equal to the fair market value of the resulting fractional share on the Conversion Date (as hereinafter defined).  For purposes of

 

7

 

Section 10 of this Warrant, shares issued pursuant to the Conversion Right shall be treated as if they were issued upon the exercise of this Warrant.

 

(b)                                 Method of Exercise.  The Conversion Right may be exercised by the holder by the surrender of this Warrant at the principal office of the Company together with a written statement (which may be in the form of Exhibit A-1 or Exhibit A-2 hereto) specifying that the holder thereby intends to exercise the Conversion Right and indicating the number of shares subject to this Warrant which are being surrendered (referred to in Section 10.2(a) hereof as the Converted Warrant Shares) in exercise of the Conversion Right.  Such conversion shall be effective upon receipt by the Company of this Warrant together with the aforesaid written statement, or on such later date as is specified therein (the “Conversion Date”), and, at the election of the holder hereof, may be made contingent upon the closing of the sale of the Company’s Common Stock to the public in a public offering pursuant to a Registration Statement under the Act (a “Public Offering”).  Certificates for the shares issuable upon exercise of the Conversion Right and, if applicable, a new warrant evidencing the balance of the shares remaining subject to this Warrant, shall be issued as of the Conversion Date and shall be delivered to the holder within thirty (30) days following the Conversion Date.

 

(c)                                  Determination of Fair Market Value.  For purposes of this Section 10.2, “fair market value” of a share of Common Stock as of a particular date (the “Determination Date”) shall mean:

 

(i)             If the Conversion Right is exercised in connection with and contingent upon a Public Offering, and if the Company’s Registration Statement relating to such Public Offering (“Registration Statement”) has been declared effective by the Securities and Exchange Commission, then the initial “Price to Public” specified in the final prospectus with respect to such offering.

 

(ii)          If the Conversion Right is not exercised in connection with and contingent upon a Public Offering, then as follows:

 

(A)                               If traded on a securities exchange, the fair market value of the Common Stock shall be deemed to be the average of the closing prices of the Common Stock on such exchange over the five trading days immediately prior to the Determination Date;

 

(B)                               If traded on the Nasdaq Stock Market or other over-the-counter system, the fair market value of the Common Stock shall be deemed to be the average of the closing prices of the Common Stock over the five trading days immediately prior to the Determination Date; and

 

(C)                               If there is no public market for the Common Stock, then fair market value shall be determined by the Company’s Board of Directors in good faith.

 

In making a determination under clauses (A) or (B) above, if on the Determination Date, five trading days had not passed since the IPO, then the fair market value of the Common Stock shall be the

 

8

 

average closing prices or closing bid prices, as applicable, for the shorter period beginning on and including the date of the IPO and ending on the trading day prior to the Determination Date (or if such period includes only one trading day, the closing price or closing bid price, as applicable, for such trading day).  If closing prices or closing bid prices are no longer reported by a securities exchange or other trading system, the closing price or closing bid price shall be that which is reported by such securities exchange or other trading system at 4:00 p.m. New York City time on the applicable trading day.

 

10.3                        Exercise Prior to Expiration.  To the extent this Warrant is not previously exercised as to all of the Shares subject hereto, and if the fair market value of one share of the Common Stock is greater than the Warrant Price then in effect, this Warrant shall be deemed automatically exercised pursuant to Section 10.2 above (even if not surrendered) immediately before its expiration.  For purposes of such automatic exercise, the fair market value of one share of Common Stock upon such expiration shall be determined pursuant to Section 10.2(c).  To the extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this Section 10.3, the Company agrees to promptly notify the holder hereof of the number of Shares, if any, the holder hereof is to receive by reason of such automatic exercise.

 

11.                               Representations and Warranties.  The Company represents and warrants to the holder of this Warrant as of the date hereof as follows:

 

(a)                                 This Warrant has been duly authorized and executed by the Company and is a valid and binding obligation of the Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing specific performance, injunctive relief and other equitable remedies.

 

(b)                                 The Shares have been duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable and free from preemptive rights, other than preemptive rights arising under the Certificate of Incorporation, which rights will be waived (or notice periods lapsed) prior to the time the Shares are issued.

 

(c)                                  The execution and delivery of this Warrant are not, and the issuance of the Shares upon exercise of this Warrant in accordance with the terms hereof will not be, inconsistent with the Company’s Certificate of Incorporation, as amended to date or the Company’s by-laws, as amended to date, do not contravene any law, governmental rule or regulation, judgment or order applicable to the Company, and do not conflict with or contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument of which the Company is a party or by which it is bound or require the consent or approval of, the giving of notice to, the registration or filing with or the taking of any action in respect of or by, any Federal, state or local government authority or agency or other person, except for the filing of notices pursuant to federal and state securities laws, which filings will be effected by the time required thereby.

 

9

 

(d)                                 There are no actions, suits, audits, investigations or proceedings pending or, to the knowledge of the Company, threatened against the Company in any court or before any governmental commission, board or authority which, if adversely determined, could have a material adverse effect on the ability of the Company to perform its obligations under this Warrant.

 

(e)                                  The number of shares of Common Stock of the Company outstanding on the date hereof, on a fully diluted basis (assuming the conversion of all outstanding convertible securities and the exercise of all outstanding options and warrants) does not exceed Fifteen Million, Seven Hundred Forty-Two Thousand, Three Hundred Eighty-Two and 75/100 (15,742,382.75) shares.

 

12.                               Modification and Waiver.  This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought.

 

13.                               Notices.  Any notice, request, communication or other document required or permitted to be given or delivered to the holder hereof or the Company shall be delivered, or shall be sent by certified or registered mail, postage prepaid, to each such holder at its address as shown on the books of the Company or to the Company at the address indicated therefor on the signature page of this Warrant.

 

14.                               Binding Effect on Successors.  The terms and conditions of this Warrant shall be binding upon (a) any transferee or successor to the holder hereof and (b) any corporation succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company’s assets.  All of the covenants and agreements of the parties hereto shall inure to the benefit of the respective successors and assigns of the parties hereto.

 

15.                               Lost Warrants or Stock Certificates.  The Company covenants to the holder hereof that, upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, the Company will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate.

 

16.                               Descriptive Headings.  The descriptive headings of the various Sections of this Warrant are inserted for convenience only and do not constitute a part of this Warrant.  The language in this Warrant shall be construed as to its fair meaning without regard to which party drafted this Warrant.

 

17.                               Governing Law.  This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of Delaware.

 

18.                               Survival of Representations, Warranties and Agreements.  All representations and warranties of the Company and the holder hereof contained herein shall survive the Date of Grant,

 

10

 

the exercise or conversion of this Warrant (or any part hereof) or the termination or expiration of rights hereunder.  All agreements of the Company and the holder hereof contained herein shall survive indefinitely until, by their respective terms, they are no longer operative.

 

19.                               Remedies.  In case any one or more of the covenants and agreements contained in this Warrant shall have been breached, the holders hereof (in the case of a breach by the Company), or the Company (in the case of a breach by a holder), may proceed to protect and enforce their or its rights either by suit in equity and/or by action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific performance of any such covenant or agreement contained in this Warrant.

 

20.                               No Impairment of Rights.  The Company will not, by amendment of its Certificate of Incorporation or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this Warrant against impairment.

 

21.                               Severability.  The invalidity or unenforceability of any provision of this Warrant in any jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provision of this Warrant, which shall remain in full force and effect.

 

22.                               Recovery of Litigation Costs.  If any legal action or other proceeding is brought for the enforcement of this Warrant, or because of an alleged dispute, breach, default, or misrepresentation in connection with any of the provisions of this Warrant, the successful or prevailing party or parties shall be entitled to recover reasonable attorneys’ fees and other costs incurred in that action or proceeding, in addition to any other relief to which it or they may be entitled.

 

23.                               Entire Agreement; Modification.  This Warrant constitutes the entire agreement between the parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations, and undertakings of the parties, whether oral or written, with respect to such subject matter.

 

11

 

The Company and Holder have caused this Second Amended and Restated Warrant to be duly executed and delivered as of the Date of Grant specified above.

 

	
 
    	
COMPANY
    
	
 
    	
 
    
	
 
    	
N30   PHARMACEUTICALS, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Tom Sokolowski
    
	
 
    	
Name:   Tom Sokolowski
    
	
 
    	
Title:   Authorized Officer
    
	
 
    	
 
    
	
 
    	
Address:
    	
3122   Sterling Circle, Suite 200
    
	
 
    	
 
    	
Boulder,   CO 80301
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
HOLDER
    
	
 
    	
 
    
	
 
    	
HORIZON   CREDIT II LLC, as successor in interest to COMPASS HORIZON FUNDING COMPANY   LLC,
    
	
 
    	
 
    
	
 
    	
By:   Compass Horizon Funding Company LLC, it sole member
    
	
 
    	
By:   Horizon Technology Finance Corporation, its sole member
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Robert D. Pomeroy, Jr.
    
	
 
    	
 
    	
Name:   Robert D. Pomeroy, Jr.
    
	
 
    	
 
    	
Title:   Chief Executive Officer
    
						

 

 

EXHIBIT A-1

 

NOTICE OF EXERCISE

 

To:                             N30 PHARMACEUTICALS, INC (the “Company”)

 

1.                                      The undersigned hereby:

 

o                                    elects to purchase                  shares of Common Stock of the Company pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full, or

 

o                                    elects to exercise its net issuance rights pursuant to Section 10.2 of the attached Warrant with respect to                  Common Stock.

 

2.                                      Please issue a certificate or certificates representing                  shares in the name of the undersigned or in such other name or names as are specified below:

 

	
 
    	
 
    	
 
    
	
 
    	
(Name)
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
(Address)
    	
 
    

 

3.                                      The undersigned represents that the aforesaid shares are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares, all except as in compliance with applicable securities laws.

 

	
 
    	
 
    
	
 
    	
(Signature)
    
	
 
    	
 
    
	
 
    	
 
    
	
(Date)
    	
 
    

 

 

EXHIBIT A-2

 

NOTICE OF EXERCISE

 

To:                             N30 PHARMACEUTICALS, INC. (the “Company”)

 

1.                                      Contingent upon and effective immediately prior to the closing (the “Closing”) of the Company’s public offering contemplated by the Registration Statement on Form S      , filed                 , 20    , the undersigned hereby:

 

o                                    elects to purchase                  shares of Common Stock of the Company (or such lesser number of shares as may be sold on behalf of the undersigned at the Closing) pursuant to the terms of the attached Warrant, or

 

o                                    elects to exercise its net issuance rights pursuant to Section 10.2 of the attached Warrant with respect to                  shares of Common Stock.

 

2.                                      Please deliver to the custodian for the selling shareholders a stock certificate representing such                  shares.

 

3.                                      The undersigned has instructed the custodian for the selling shareholders to deliver to the Company $                 or, if less, the net proceeds due the undersigned from the sale of shares in the aforesaid public offering.  If such net proceeds are less than the purchase price for such shares, the undersigned agrees to deliver the difference to the Company prior to the Closing.

 

	
 
    	
 
    
	
 
    	
(Signature)
    
	
 
    	
 
    
	
 
    	
 
    
	
(Date)Exhibit 4.4

 

EXECUTION COPY

 

SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT

 

THIS SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of November 18, 2014, by and among N30 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the holders of capital stock of the Company listed on Schedule A hereto (each a “Stockholder” and together the “Stockholders”).

 

BACKGROUND

 

WHEREAS, the Company and certain of the Stockholders entered into that certain Amended and Restated Investor Rights Agreement, dated as of September 23, 2014 (the “Prior Rights Agreement”);

 

WHEREAS, certain of the Stockholders are parties to the Series 2 Preferred Stock Purchase Agreement of even date herewith, among the Company and the purchasers party thereto (the “Purchase Agreement”), and it is a condition to the closing of the sale of the Company’s Series 2 Preferred Stock (as defined below) that the Stockholders and the Company execute and deliver this Agreement;

 

WHEREAS, the parties to the Prior Rights Agreement desire to amend and restate the Prior Rights Agreement in its entirety as set forth herein and accept the rights and covenants in this Agreement in lieu of their rights and covenants under the Prior Rights Agreement; and

 

WHEREAS, the terms of the Prior Rights Agreement may be amended and restated only by a written instrument executed by the Company and (i) the holders of a majority of the Registrable Securities then outstanding and (ii) a Supermajority in Voting Interest (as defined in the Prior Rights Agreement), and the signatories hereto include such holders;

 

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, and other consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

 

1.              DEFINITIONS.  For purposes of this Agreement:

 

1.1.                            “Affiliate” means any Person that (a) directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the Person specified, (b) owns or controls ten percent (10%) or more of the outstanding voting securities of the specified Person, (c) is an officer, director, general partner or managing member of the specified Person, or (d) if the specified Person is an officer, director, general partner or managing member, any entity for which the specified Person acts in such capacity.  The term “control” (including the terms “controlling,” “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management or the policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

 

1.2.                            “Bad Actor Disqualification” means any “bad actor” disqualification described in Rule 506(d)(1)(i) through (viii) under the Securities Act.

 

 

1.3.                            “Board of Directors” means the board of directors of the Company.

 

1.4.                            “Common Stock” means shares of the Company’s common stock, par value $0.001 per share.

 

1.5.                             “Damages” means any loss, damage, claim, expense or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim, expense or liability (or any action in respect thereof) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.

 

1.6.                            “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

1.7.                            “Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to a transaction subject to SEC Rule 145; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.

 

1.8.                             “Excluded Securities” means Securities comprised of the following: (i) Securities that are issued pursuant to an equity split, dividend, reclassification or subdivision of the equity interests of the Company; (ii) Securities that are issued pursuant to any equipment loan or leasing arrangement, real property leasing arrangement or debt financing from a bank or similar financial institution approved by the Board of Directors, including without limitation, Securities issuable pursuant to that certain Warrant to Purchase Qualified Units issued to Compass Horizon Funding Company LLC on February 18, 2011 and the amended and restated warrants issued to Horizon Credit I LLC and Horizon Credit II LLC on August 1, 2012 in place of such warrant; (iii) Securities that are issued for consideration pursuant to a merger, consolidation, acquisition, license, development agreement, strategic alliance or partnership, joint venture or business combination approved by the Board of Directors; (iv) Securities issued or issuable with the affirmative vote or written consent of a Supermajority in Voting Interest in favor of a resolution that expressly states that such Securities are to be considered Excluded Securities; (v) Securities issued to employees, directors, consultants and other services providers of the Company pursuant to a plan, agreement or arrangement approved by the Board of Directors; (vi) Securities issued in an IPO; and (vii) Securities issued in exchange for or upon

 

2

 

exercise of any outstanding options, warrants or other convertible securities issued as of the date hereof.

 

1.9.                            “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC.

 

1.10.                     “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC.

 

1.11.                     “GAAP” means generally accepted accounting principles in the United States.

 

1.12.                     “Holder” means any holder of Registrable Securities who is a party to this Agreement.

 

1.13.                     “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, of a natural person referred to herein.

 

1.14.                     “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.

 

1.15.                     “IPO” means the Company’s first underwritten public offering of its Common Stock under the Securities Act.

 

1.16.                     “Major Investors” means each holder of at least three hundred thousand (300,000) shares of Preferred Stock, each Wellington Investor, Sabby Healthcare Master Fund, Ltd., Tiger Partners, L.P., a Delaware limited partnership, Katherine M. Snider and/or the Estate of Arnold Snider, III, Deerfield PDI Financing, L.P., Deerfield Special Situations International Master Fund L.P., Deerfield Private Design Fund, L.P., Deerfield Private Design International, L.P., Deerfield Special Situations Fund, L.P., Roberto Mignone and Swiftcurrent Partners, L.P.

 

1.17.                     “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

1.18.                      “Preferred Stock” means, collectively, the shares of the Company’s Series 1 Preferred Stock and Series 2 Preferred Stock.

 

1.19.                      “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of any (A) Preferred Stock; and (B) the Common Stock issued upon exercise of that certain Amended and Restated Warrant issued to Horizon Credit I LLC on August 1, 2012 and that certain Amended and Restated Warrant issued to Horizon Credit II LLC on August 1, 2012 (collectively, the “Horizon Warrant Shares”); provided however, that none of the Horizon Warrant Shares may be included for purposes of initiating a request under Section 2

 

3

 

hereof or included in any request by Initiating Holders; and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i) above; excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.12 of this Agreement.

 

1.20.                     “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are, or are convertible into, Registrable Securities.

 

1.21.                     “SEC” means the Securities and Exchange Commission.

 

1.22.                     “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.

 

1.23.                     “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.

 

1.24.                     “Securities” means and include any equity securities of the Company, by whatever name called, whether or not currently authorized, and any securities, options, warrants, rights or similar instruments convertible into or exchangeable or exercisable for any such equity securities.

 

1.25.                     “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

1.26.                     “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6.

 

1.27.                     “Series 1 Preferred Stock” mean the Company’s Series 1 Preferred Stock, par value of $0.001 per share.

 

1.28.                     “Series 2 Preferred Stock” mean the Company’s Series 2 Preferred Stock, par value of $0.001 per share.

 

1.29.                      “Supermajority in Voting Interest” means both (i) Stockholders holding at least 60% of the shares of Common Stock issued or issuable upon conversion of the Series 1 Preferred Stock and (ii) Stockholders holding at least a majority of the shares of Common Stock issued or issuable upon conversion of the Series 2 Preferred Stock.

 

1.30.                     “Wellington Investors” shall mean any Stockholders advised by Wellington Management Company, LLP or one of its Affiliates.

 

4

 

2.              REGISTRATION RIGHTS.

 

2.1.                            Demand Registration.

 

(a)                                 Form S-1 Demand.  If at any time after the earlier of (i) five (5) years after the date of this Agreement and (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of at least 40% of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to at least thirty-five percent (35%) of the Registrable Securities then outstanding, then the Company shall (i) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within ninety (90) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3.

 

(b)                                 Form S-3 Demand.  If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least thirty percent (30%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $3 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(c) and Section 2.3.

 

(c)                                  Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to be filed and it is therefore necessary to defer the filing of such registration statement, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such ninety (90) day period other than an Excluded Registration.

 

(d)                                 The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a) (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided,

 

5

 

that the Company is actively employing good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Section 2.1(a) and/or Section 2.1(b); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b).  The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided, that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Section 2.1(a) and/or Section 2.1(b).  A registration shall not be counted as “effected” for purposes of this Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Section 2.1(d).

 

2.2.                            Company Registration.  If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration.  Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration.  The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration.  The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6.

 

2.3.                            Underwriting Requirements.

 

(a)                                 If, pursuant to Section 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such information in the Demand Notice.  The underwriter(s) will be selected by a majority in interest of the Initiating Holders and shall be reasonably acceptable to the Company.  In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein.  All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting.  Notwithstanding any other provision of this Section 2.3, if the underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of

 

6

 

Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting.  To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares.

 

(b)                                 In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company.  If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering.  If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders.  To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares.  Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below twenty percent (20%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering.  For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence.

 

(c)                                  For purposes of Section 2.1, a registration shall not be counted as “effected” if, (i) as a result of an exercise of the underwriter’s cutback provisions in Section 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders

 

7

 

have requested to be included in such registration statement are actually included, (ii) a registration statement with respect thereto shall not have become effective, (iii) after it has become effective, such registration is interfered with for any reason by any stop order, injunction or other order or requirement of the SEC or any other governmental agency or any court, and the result of such interference is to prevent the holders of Registrable Securities to be sold thereunder from disposing thereof in accordance with the intended methods of disposition, or (iv) the conditions to closing specified in the underwriting agreement or purchase agreement entered into in connection with any underwritten registration shall not be satisfied or waived with the consent of the holders of a majority of the Registrable Securities that were to have been sold thereunder, other than as a result of a breach by any holder of its obligations thereunder or hereunder.

 

2.4.                            Obligations of the Company.  Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:

 

(a)                                 prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred eighty (180) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that (i) such one hundred eighty (180) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred eighty (180) day period shall be extended for up to an additional one hundred eighty (180) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold;

 

(b)                                 prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;

 

(c)                                  furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;

 

(d)                                 use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;

 

8

 

(e)                                  in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering;

 

(f)                                   use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed;

 

(g)                                  provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;

 

(h)                                 promptly make available for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith;

 

(i)                                     notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed;

 

(j)                                    after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus; and

 

(k)                                 promptly notify each seller of Registrable Securities, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, upon discovery that, or upon the discovery of the happening of any event as a result of which, the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances under which they were made, and at the request of any such seller promptly prepare and furnish to such seller a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such securities, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances under which they were made.

 

2.5.                            Furnish Information.  It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information

 

9

 

regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities.

 

2.6.                            Expenses of Registration.  All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $100,000 of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Section 2.1(a) or Section 2.1(b), as the case may be.  All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.

 

2.7.                            Delay of Registration.  No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.

 

2.8.                            Indemnification.  If any Registrable Securities are included in a registration statement under this Section 2:

 

(a)                                 To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, stockholders and investment advisors of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration.

 

(b)                                 To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its

 

10

 

officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.

 

(c)                                  Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, give the indemnifying party notice of the commencement thereof.  The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action.  The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially prejudices the indemnifying party’s ability to defend such action.  The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this Section 2.8.

 

(d)                                 To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims,

 

11

 

damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations.  The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case, (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11 (f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder.

 

(e)                                  Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control.

 

(f)                                   Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.

 

2.9.                            Reports Under Exchange Act.  With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall:

 

(a)                                 make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed by the Company for the IPO;

 

(b)                                 use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and

 

(c)                                  furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company

 

12

 

that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).

 

2.10.                     Limitations on Subsequent Registration Rights.  From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that provide registration rights that are superior or equal in priority to, or inconsistent with, the registration rights provided to Holders hereunder.

 

2.11.                     “Market Stand-off” Agreement.  Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days (or such longer period as the managing underwriter shall request in order to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation)), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise.  The foregoing provisions of this Section 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers and directors and stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions.  The underwriters in connection with such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power, and authority to enforce the provisions hereof as though they were a party hereto.  Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto.  If any of the obligations described in this Section 2.11 are waived or terminated with respect to any of the securities of any such Holder, officer, director or greater-than-one-percent stockholder (in any such case, the “Released Securities”), the foregoing provisions shall be waived or terminated, as applicable, to the same extent and

 

13

 

with respect to the same percentage of securities of each Holder as the percentage of Released Securities represent with respect to the securities held by the applicable Holder, officer, director or greater-than-one-percent stockholder.

 

2.12.                     Termination of Registration Rights.  The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.1 or Section 2.2 shall terminate upon the earliest to occur of:

 

(a)                                 the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, unless, following, and as a result of, such Deemed Liquidation Event, the Holders hold “restricted securities” (as defined under SEC Rule 144); and

 

(b)                                 following the IPO, when all of such Holder’s Registrable Securities could be sold without restriction under SEC Rule 144 (without the requirement for the Company to be in compliance with the current public information required under Rule 144(c)(1)) or another similar exemption under the Securities Act.

 

2.13.                     Restrictions on Transfer.

 

(a)                                 The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act.  A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144 to be bound by the terms of this Agreement if the transferred shares do not remain Registrable Securities hereunder following such transfer.

 

(b)                                 Each certificate, instrument, or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.13(c)) (collectively, the “Restricted Securities”) be notated with a legend substantially in the following form:

 

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933.  SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.

 

THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT

 

14

 

BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.

 

The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.13.

 

(c)                                  The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this Section 2.  Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, or, following the IPO, the transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer.  Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed  sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company.  The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that, with respect to transfers under the foregoing clause (y),  each transferee agrees in writing to be subject to the terms of this Subsection 2.13.  Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144 or pursuant to an effective registration statement, the appropriate restrictive legend set forth in Subsection 2.13(b), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act.

 

(d)                                 Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition of any securities of the Company, or any beneficial interest therein, to any person (other than the Company) that, to such Holder’s knowledge, is (or, as a result of such proposed transfer will become) a beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, unless and until the proposed transferee confirms to the reasonable satisfaction of the Company that neither the proposed transferee nor any of its directors, executive officers, general partners or managing members nor any person that would be deemed a beneficial owner of 20% or more of the Company’s voting securities (in accordance with Rule 506(d) of the Securities Act) is subject to any Bad Actor

 

15

 

Disqualification, except as set forth in Rule 506(d)(2) or (d)(3) under the Securities Act and disclosed, reasonably in advance of the transfer, in writing in reasonable detail to the Company.

 

3.              RIGHT OF FIRST OFFER. Subject to (a) the terms and conditions of this Section 3.1, and (b) the provisions of the Company’s Certificate of Incorporation regarding approval of the issuance or sale of any Securities, if the Company or any of its subsidiaries proposes to offer, sell or otherwise issue (or enter into any agreement related to any of the foregoing) to any existing Stockholder or any other Person any Securities, as well as rights, options, or warrants to purchase such Securities, or securities of any type whatsoever (including equity or debt securities) that are, or may become, convertible or exchangeable into or exercisable for such Securities (collectively “New Securities”), other than Excluded Securities, then the Company shall first offer such New Securities to all the Major Investors.

 

3.1.                            Notice.  The Company shall give written notice (the “Offer Notice”) to the Major Investors, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which the Company proposes to offer such New Securities.

 

3.2.                            Exercise.  By written notification to the Company within twenty (20) days after the Offer Notice is given, each of the Major Investors may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which is proportional to the ratio of Securities held by or issuable (directly or indirectly) to such Major Investors and their Affiliates to the total number of Securities then outstanding (assuming full conversion or exercise of all options, warrants and other derivative securities then outstanding).   At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise.  During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the ratio of Securities held by or issuable (directly or indirectly) to such Fully Exercising Investors to the total number of Securities then outstanding (assuming full conversion or exercise of all options, warrants and other derivative securities then outstanding) held by all Fully Exercising Investors who wish to purchase such unsubscribed shares.  The closing of any sale pursuant to this Subsection 3.2 shall occur within the later of ninety (90) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 3.3.

 

3.3.                            Sale by Company.  If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Section 3.2, the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 3.2, offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice.  If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within the earlier of: (i) sixty (60) days of the execution thereof and (ii) one hundred eighty (180) days following the expiration of

 

16

 

the periods provided in Section 3.2, the right provided under this Section shall be deemed to be revived, and such New Securities shall not be offered unless first reoffered to all of the Major Investors in accordance with this Section 3.

 

3.4.                            Termination. The covenants set forth in this Section 3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first.

 

3.5.                            Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of this Section 3, the Company may elect to give notice to the Major Investors within thirty (30) days after the issuance of New Securities.  Such notice shall describe the type, price and terms of the New Securities.  Each Major Investor shall have twenty (20) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by such Major Investor, maintain such Person’s percentage ownership position, calculated as set forth in Section 3.2 before giving effect to the issuance of such New Securities.  The closing of such sale shall occur within sixty (60) days of the date notice is given to the Major Investors.

 

3.6.                            Each of the undersigned parties hereto hereby waives the right of first offer set forth in Section 3 of the Prior Rights Agreement with respect to the issuance of shares of Series 2 Preferred Stock under the Purchase Agreement, including any notice requirements related thereto.

 

4.              COVENANTS.

 

4.1.                            Compensation.  The Company shall reimburse each member of the Board of Directors for reasonable travel and other out-of-pocket expenses incurred to attend meetings of the Board of Directors and committees thereof and in performing Company-approved business.

 

4.2.                            Meetings of Board.  Meetings of the Board of Directors shall be held at least twice per year at places within or without the State of Delaware and at times fixed by resolution of the Board of Directors.

 

4.3.                            “Bad Actor” Notice.  Each party to this Agreement will promptly notify each other party to this Agreement in writing if it becomes subject to any Bad Actor Disqualification; provided, however, that, with respect to the Stockholders, such obligation under this Section 4.3 shall apply only if such Stockholder beneficially owns 20% or more of the Company’s outstanding voting securities, calculated on the basis of voting power.

 

4.4.                            Reporting.  The Company will deliver to the Board of Directors and each Major Investor the following:

 

(a)                                 Audited Annual Financials.  As soon as available, but in any event within 120 days after the end of each fiscal year of the Company, a balance sheet of the Company as at the end of such fiscal year, and the related statements of operations, stockholders’

 

17

 

equity and cash flows for the Company for such fiscal year, setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and prepared in accordance with GAAP, audited and accompanied by a report and opinion of an independent public accounting firm, which report and opinion shall be prepared in accordance with generally accepted auditing standards;

 

(b)                                 Unaudited Quarterly Financials.  As soon as available, but in any event within 30 days after the end of each of the first three fiscal quarters of each fiscal year of the Company, (i) a balance sheet of the Company as at the end of such fiscal quarter, and (ii) the related statements of operations of the Company for such fiscal quarter and for the portion of the fiscal year then ended, and (iii) statements of cash flows of the Company for the portion of the fiscal year then ended, setting forth in each case in comparative form the figures for the corresponding fiscal quarter of the previous fiscal year and the corresponding portion of the previous fiscal year;

 

(c)                                  Capitalization.  As soon as practicable, but in any event within 30 days after the end of each of the first three fiscal quarters of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company; and

 

(d)                                 Budgets.  Commencing for the year ended December 31, 2015, as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal year, approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company.

 

4.5.                            Inspection.  The Company shall permit each Major Investor (provided that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, each during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that the Company shall not be obligated pursuant to this Subsection 4.5 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.

 

4.6.                            Non-Disclosure.  Each Stockholder agrees that, except as otherwise consented to by the Board of Directors, all non-public information furnished to such Stockholder pursuant to this Agreement will be kept confidential and will not be used or disclosed by such Stockholder, or by any of such Stockholder’s agents, representatives, investment advisors or

 

18

 

employees, in any manner, in whole or in part, except that (i) each Stockholder shall be permitted to disclose such information to those of such Stockholder’s agents, representatives, investment advisors and employees who need to be familiar with such information in connection with such Stockholder’s investment in the Company and who are charged with an obligation of confidentiality, (ii) each Stockholder shall be permitted to disclose such information to such Stockholder’s direct or indirect partners and equity holders or potential equity holders or partners provided that such Stockholder  informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information, (iii) each Stockholder shall be permitted to disclose information to the extent required by law, so long as such Stockholder shall have first provided the Company a reasonable opportunity to contest the necessity of disclosing such information, (iv) each Stockholder shall be permitted to disclose information to the extent necessary for the enforcement of any right of such Stockholder arising under this Agreement, and (v) each Stockholder shall be permitted to disclose information generally available to or known by the public (other than as a result of disclosure in violation hereof).

 

4.7.                            Employee Agreements.  Within a reasonable period of time following the Initial Closing (as defined in the Purchase Agreement), which shall in no event exceed thirty (30) days, the Company will (i) adopt new forms of confidential information and invention assignment agreement (each, an “Assignment Agreement”) to be entered into by the Company and each of its employees, consultants and contractors who has access to the Company’s confidential information and/or trade secrets (each, a “Service Provider”), in forms which shall have been approved by the Board of Directors with the advice of counsel and provided to any Stockholder requesting to review the same prior to the Initial Closing, and (ii) enter into an Assignment Agreement with each such Service Provider. The Company will cause each person hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to the Company’s confidential information and/or trade secrets to enter into an Assignment Agreement.

 

5.              MISCELLANEOUS.

 

5.1.                            Successors and Assigns.  The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities; provided, however, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11.  The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties.  Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein.

 

5.2.                            Governing Law.  This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all

 

19

 

other matters shall be governed by and construed in accordance with the internal laws of the State of New York, without regard to conflict of law principles that would result in the application of any law other than the law of the State of New York.

 

5.3.                            Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

5.4.                            Titles and Subtitles.  The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement.

 

5.5.                            Notices.  All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or: (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt.  All communications shall be sent to the respective parties at their addresses as set forth on the signature pages, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 5.5.  If notice is given to the Company, a copy shall also be sent to King & Spalding LLP, 601 South California Avenue, Suite 100, Palo Alto, CA  94304, Attn: Laura Bushnell, fax (650) 422-6800, email: lbushnell@kslaw.com.

 

5.6.                            Amendments and Waivers.  Any term of Section 2 of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of a majority of the Registrable Securities then outstanding; provided that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.  Any term (other than Section 2) of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a written instrument executed by (a) the Company; and (b) a Supermajority in Voting Interest; provided that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.    Notwithstanding the foregoing, (i) this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Stockholder without the written consent of such Stockholder, unless such amendment, termination, or waiver applies to all Stockholders in the same fashion and (ii) any amendment, waiver or termination of Section 2.11, Section 4.4 or Section 4.5 that adversely affects the Wellington Investors shall require the prior written consent of the Wellington Investors.  The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in

 

20

 

writing to such amendment, termination, or waiver.  Any amendment, termination, or waiver effected in accordance with this Section 5.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto.  No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.

 

5.7.                            Severability.  In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.

 

5.8.                            Aggregation of Stock.  All Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.

 

5.9.                            Entire Agreement.  Upon the effectiveness of this Agreement, the Prior Rights Agreement shall be deemed amended and restated to read in its entirety as set forth in this Agreement. This Agreement constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.

 

5.10.                     Dispute Resolution.  The parties (a) hereby irrevocably and unconditionally submit to the non-exclusive jurisdiction of the federal and state courts located within the geographic boundaries of the United States District Court for the Southern District of New York for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement and (b) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

5.11.                     Delays or Omissions.  No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring.  All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 

[Remainder of Page Intentionally Left Blank]

 

21

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
COMPANY:
    
	
 
    	
 
    
	
 
    	
N30 PHARMACEUTICALS, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Tom Sokolowski
    
	
 
    	
Name:   
    	
Tom   Sokolowski
    
	
 
    	
Title:   
    	
Chief   Financial Officer
    

 

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
 
    	
JENNISON   GLOBAL HEALTHCARE
    
	
 
    	
MASTER   FUND, LTD.
    
	
 
    	
 
    
	
 
    	
By:   
    	
Jennison   Associates LLC, as the
    
	
 
    	
 
    	
Investment   Manager of the Fund
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   David Chan
    
	
 
    	
 
    	
Name:
    	
David   Chan
    
	
 
    	
 
    	
Title:
    	
Managing Director of
    
	
 
    	
 
    	
 
    	
Jennison Associates LLC
    

 

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
 
    	
RA   CAPITAL HEALTHCARE FUND, LP
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Peter Kolchinsky
    
	
 
    	
 
    	
Name:
    	
Peter   Kolchinsky
    
	
 
    	
 
    	
Title:
    	
Manager
    

 

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
 
    	
ROCK   SPRINGS CAPITAL MASTER
    
	
 
    	
FUND   LP
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Graham McPhall
    
	
 
    	
 
    	
Name:
    	
Graham   McPhall
    
	
 
    	
 
    	
Title:
    	
Managing Director
    
	
 
    	
 
    	
 
    	
Rock Springs Capital
    
	
 
    	
 
    	
 
    	
650 S. Exeter St., Suite 1070
    
	
 
    	
 
    	
 
    	
Baltimore, MD 21202
    

 

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
 
    	
SABBY   HEALTHCARE MASTER FUND,
    
	
 
    	
LTD.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Robert Grundstein
    
	
 
    	
 
    	
Name:
    	
Robert   Grundstein
    
	
 
    	
 
    	
Title:
    	
COO of Investment Management
    

 

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
 
    	
GLOBAL   HEALTH CARE
    
	
 
    	
OPPORTUNITY   LTD.
    
	
 
    	
 
    
	
 
    	
By:   
    	
Wellington   Management Company, LLP
    
	
 
    	
 
    	
its   investment adviser
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Steven M. Hoffman 
    
	
 
    	
 
    	
Name:
    	
Steven   M. Hoffman 
    
	
 
    	
 
    	
Title:
    	
Vice President and Counsel
    
	
 
    	
 
    
	
 
    	
HADLEY   HARBOR MASTER INVESTORS 
    
	
 
    	
(CAYMAN)   L.P.
    
	
 
    	
By:
    	
Wellington   Management Company, LLP
    
	
 
    	
 
    	
its   investment adviser
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Steven M. Hoffman 
    
	
 
    	
 
    	
Name:
    	
Steven   M. Hoffman 
    
	
 
    	
 
    	
Title:
    	
Vice President and Counsel
    
	
 
    	
 
    
	
 
    	
HAWKES   BAY MASTER INVESTORS
    
	
 
    	
(CAYMAN)   LP
    
	
 
    	
 
    
	
 
    	
By:   
    	
Wellington   Management Company, LLP
    
	
 
    	
 
    	
its   investment adviser
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Steven M. Hoffman 
    
	
 
    	
 
    	
Name:
    	
Steven   M. Hoffman 
    
	
 
    	
 
    	
Title:
    	
Vice President and Counsel
    

 

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
 
    	
NORTH   RIVER INVESTORS (BERMUDA) L.P.
    
	
 
    	
 
    
	
 
    	
By:   
    	
Wellington   Management Company, LLP
    
	
 
    	
 
    	
its   investment adviser
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Steven M. Hoffman 
    
	
 
    	
 
    	
Name:
    	
Steven   M. Hoffman 
    
	
 
    	
 
    	
Title:
    	
Vice President and Counsel
    
	
 
    	
 
    
	
 
    	
NORTH   RIVER PARTNERS, L.P.
    
	
 
    	
 
    
	
 
    	
By:   
    	
Wellington   Management Company, LLP
    
	
 
    	
 
    	
its   investment adviser
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Steven M. Hoffman 
    
	
 
    	
 
    	
Name:
    	
Steven   M. Hoffman 
    
	
 
    	
 
    	
Title:
    	
Vice President and Counsel
    
	
 
    	
 
    
	
 
    	
SALTHILL   INVESTORS (BERMUDA) L.P.
    
	
 
    	
 
    
	
 
    	
By:   
    	
Wellington   Management Company, LLP
    
	
 
    	
 
    	
its   investment adviser
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Steven M. Hoffman 
    
	
 
    	
 
    	
Name:
    	
Steven   M. Hoffman 
    
	
 
    	
 
    	
Title:
    	
Vice President and Counsel
    
	
 
    	
 
    
	
 
    	
SALTHILL   PARTNERS, L.P.
    
	
 
    	
 
    
	
 
    	
By:   
    	
Wellington   Management Company, LLP
    
	
 
    	
 
    	
its   investment adviser
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Steven M. Hoffman 
    
	
 
    	
 
    	
Name:
    	
Steven   M. Hoffman 
    
	
 
    	
 
    	
Title:
    	
Vice President and Counsel
    

 

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
 
    	
COWEN   INVESTMENTS LLC
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Stephen Lasota
    
	
 
    	
 
    	
Name:
    	
Stephen   Lasota
    
	
 
    	
 
    	
Title:
    	
Chief Financial Officer
    
	
 
    	
 
    	
 
    	
Cowen Group, Inc.
    

 

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
 
    	
APPLE   TREE PARTNERS IV, L.P.
    
	
 
    	
 
    
	
 
    	
By:   
    	
ATP   III GP, Ltd.
    
	
 
    	
Its:
    	
General   Partner
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Seth L. Harrison
    
	
 
    	
 
    	
Seth   L. Harrison, Director
    

 

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
 
    	
TIGER   PARTNERS, L.P.,
    
	
 
    	
 
    
	
 
    	
a   Delaware limited partnership
    
	
 
    	
 
    
	
 
    	
By:
    	
TIGER   MANAGEMENT L.L.C.,
    
	
 
    	
 
    	
its   Investment Manager
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    	
By:
    	
/s/   Michael Treisman
    
	
 
    	
 
    	
Name:
    	
Michael   Treisman
    
	
 
    	
 
    	
Title:
    	
Authorized Signatory
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
ESTATE   OF ARNOLD H. SNIDER, III
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
/s/   Katherine M. Snider
    
	
 
    	
 
    	
Katherine   M. Snider, Executor
    
						

 

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
 
    	
DEERFIELD   SPECIAL SITUATIONS FUND, L.P.
    
	
 
    	
 
    
	
 
    	
DEERFIELD   SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.
    
	
 
    	
 
    
	
 
    	
DEERFIELD   PRIVATE DESIGN FUND, L.P.
    
	
 
    	
 
    
	
 
    	
DEERFIELD   PRIVATE DESIGN FUND II, L.P.
    
	
 
    	
 
    
	
 
    	
DEERFIELD   PDI FINANCING, L.P.
    
	
 
    	
 
    
	
 
    	
DEERFIELD   PRIVATE DESIGN INTERNATIONAL, L.P.
    
	
 
    	
 
    
	
 
    	
DEERFIELD   PRIVATE DESIGN INTERNATIONAL II, L.P.
    
	
 
    	
 
    
	
 
    	
DEERFIELD   PRIVATE DESIGN INTERNATIONAL III, L.P.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
Deerfield   Mgmt, L.P., General Partner
    
	
 
    	
By:   
    	
J.   E. Flynn Capital, LLC, General Partner
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
 
    	
By:   
    	
/s/   David J. Clark
    
	
 
    	
 
    	
Name:
    	
David   J. Clark
    
	
 
    	
 
    	
Title:
    	
Authorized Signatory
    
						

 

SIGNATURE PAGE TO INVESTOR RIGHTS AGREEMENT

 

 

IN WITNESS WHEREOF, the parties have executed this Second Amended and Restated Investor Rights Agreement as of the date first written above.

 

	
 
    	
INVESTORS:
    
	
 
    	
 
    
	
 
    	
SWIFTCURRENT   PARTNERS, L.P.,
    
	
 
    	
a   Delaware limited partnership
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Roberto Mignone
    
	
 
    	
 
    	
Name:
    	
Roberto   Mignone
    
	
 
    	
 
    	
Title: 
    	
Managing Member of
    
	
 
    	
 
    	
 
    	
Bridger Capital, LLC
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
DUKE MEDICAL STRATEGIES, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:   
    	
/s/   Ellen McCarthy Steinour
    
	
 
    	
 
    	
Name:
    	
Ellen   McCarthy Steinour
    
	
 
    	
 
    	
Title:
    	
Treasurer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ Charles Scoggin, M.D.
    
	
 
    	
Charles Scoggin, M.D.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ Roberto Mignone
    
	
 
    	
Roberto   Mignone
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/   Jonathan S. Stamler, M.D.
    
	
 
    	
Jonathan   S. Stamler, M.D.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ Robert M. Califf, M.D.
    
	
 
    	
Robert M. Califf, M.D.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ Victoria Christian
    
	
 
    	
Victoria Christian

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]